Matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia in chronic phase: comparison of ex vivo and in vivo T-cell depletion

Autor: Jo, Cullis, Rm, Szydlo, Nc, Cross, Di, Marks, Ap, Schwarer, Tp, Hughes, Mackinnon S, Geoff Hale, Waldmann H, Jm, Hows

Publikováno v: Europe PubMed Central

Between January 1985 and March 1992, 48 patients with chronic phase CML underwent BMT from volunteer unrelated donors (MUD) serologically identical at HLA-A, B and DR loci. 19 patients received donor marrow ex vivo T-cell depleted (EX-TCD) with Campa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::d1520bc86e75e72d7f08f54988712af8
https://pubmed.ncbi.nlm.nih.gov/8448531

Persistence of BCR/ABL transcripts after BMT for CML detected by PCR reflects a high risk of relapse

Autor: Tp, Hughes, O'Shea P, gareth morgan, Martiat P, Jm, Goldman

Publikováno v: Europe PubMed Central

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::e9c6e0bc11a77296de4b97feed3da0cd
http://europepmc.org/abstract/med/1878700

Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study.

Autor: Hughes TP; South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia. Tim.Hughes@sahmri.com., Saglio G; Department of Clinical and Biological Sciences, University of Turin, Turin, Italy., Geissler J; CML Advocates Network, Bern, Switzerland., Kim DW; Uijeongbu Eulji Medical Center, Geumo-Dong, Uijeongbu-si, South Korea., Lomaia E; Almazov National Medical Research Centre, St Petersburg, Russia., Mayer J; Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University, and University Hospital Brno, Brno, Czech Republic., Turkina A; National Medical Research Center for Hematology, Moscow, Russia., Kapoor S; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Cardoso AP; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Nieman B; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Quenet S; Novartis Pharmaceuticals Corporation, Basel, Switzerland., Cortes JE; Georgia Cancer Center, Augusta, GA, USA.

Publikováno v: Journal of hematology & oncology [J Hematol Oncol] 2024 Dec 18; Vol. 17 (1), pp. 125. Date of Electronic Publication: 2024 Dec 18.

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study.

Autor: Yeung DT; Haematology Department, Royal Adelaide Hospital, Adelaide Medical School, University of Adelaide and Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia., Shanmuganathan N; Haematology Department, Royal Adelaide Hospital, Adelaide Medical School, University of Adelaide and Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia., Reynolds J; The Alfred Hospital and Australian Centre for Blood Diseases, Monash University, Melbourne, Australia., Branford S; Department of Genetics and Molecular Pathology, SA Pathology and Centre for Cancer Biology, University of South Australia, and Adelaide Medical School, University of Adelaide, Adelaide, Australia., Walia M; Australasian Leukaemia and Lymphoma Group, Melbourne, Australia., Yong ASM; Haematology Department, Royal Perth Hospital and University of Western Australia, Perth, Australia., Shortt J; Monash Haematology, Monash Health and Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia., Chee L; Department of Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre and Department of Medicine, University of Melbourne, Melbourne, Australia., Viiala N; Haematology Department, Liverpool Hospital and University of New South Wales, Sydney, Australia., Cunningham I; Haematology Department, Concord Hospital and University of Sydney, Sydney, Australia., Ross DM; Haematology Department, Royal Adelaide Hospital, Adelaide Medical School, University of Adelaide and Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia.; Haematology Department, Flinders Medical Centre and Flinders University, Adelaide, Australia., D'Souza A; Haematology Department, Wellington Hospital and University of Otago, Wellington, New Zealand., Wright M; Haematology Department, Fiona Stanley Hospital and University of Western Australia, Perth, Australia., Harrup R; Haematology Department, Royal Hobart Hospital and University of Tasmania, Hobart, Australia., Forsyth C; Haematology Department, Gosford Hospital, Gosford, Australia., Filshie R; Haematology Department, St Vincent's Hospital and University of Melbourne, Melbourne, Australia., Lane S; Cancer Care Services, Royal Brisbane and Women's Hospital and University of Queensland, Brisbane, Australia., Browett P; Haematology Department, Auckland Hospital and University of Auckland, Auckland, New Zealand., Grove C; Haematology Department, Sir Charles Gardiner Hospital and PathWest, University of Western Australia, Perth, Australia., Grigg AP; Haematology Department, Austin Hospital and University of Melbourne, Melbourne, Australia., Hughes TP; Haematology Department, Royal Adelaide Hospital, Adelaide Medical School, University of Adelaide and Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia.

Publikováno v: Blood [Blood] 2024 Nov 07; Vol. 144 (19), pp. 1993-2001.

Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.

Autor: Cortes JE; Georgia Cancer Center at Augusta University, Augusta, GA, USA. Jorge.Cortes@Augusta.edu., Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kim DW; Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si, South Korea., Hughes TP; South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia., Etienne G; Department of Hematology, Institut Bergonié, Bordeaux, France., Mauro MJ; Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Hochhaus A; Hematology/Oncology, Universitätsklinikum Jena, Jena, Germany., Lang F; Department of Medicine, Hematology and Oncology, Goethe University Hospital, Frankfurt, Germany., Heinrich MC; Portland VA Health Care System and OHSU Department of Medicine, Division of Hematology and Oncology, Knight Cancer Institute, Portland, OR, USA., Breccia M; Department of Translational and Precision Medicine-Az., Policlinico Umberto I-Sapienza University, Rome, Italy., Deininger M; Versiti Blood Research Institute, Milwaukee, WI, USA., Goh YT; Department of Haematology, Singapore General Hospital, Bukit Merah, Singapore., Janssen JJWM; Radboud University Medical Center, Nijmegen, The Netherlands., Talpaz M; Division of Hematology-Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA., de Soria VGG; Hospital Universitario La Princesa, Madrid, Spain., le Coutre P; Department of Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany., DeAngelo DJ; Dana-Farber Cancer Institute, Boston, MA, USA., Damon A; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Cacciatore S; Novartis Pharma AG, Basel, Switzerland., Polydoros F; Novartis Pharma AG, Basel, Switzerland., Agrawal N; Novartis Pharma AG, Basel, Switzerland., Rea D; Department of Hématologie, Hôpital Saint-Louis, Paris, France.

Publikováno v: Leukemia [Leukemia] 2024 Jul; Vol. 38 (7), pp. 1522-1533. Date of Electronic Publication: 2024 May 16.